Nivolumab in Patients With High-Risk Biochemically Recurrent Prostate Cancer

Part of paid clinical trials in Boston, Massachusetts.

Sponsor
Beth Israel Deaconess Medical Center
Study ID
NCT03637543
Phase
PHASE2
Status
Active Not Recruiting

Conditions

Eligibility Criteria

Sex
MALE
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Nivolumab — DRUG
    Nivolumab is an antibody inhibitor of the programmed death-1 (PD-1) pathway. By blocking PD-1, this medication may allow the immune system to recognize and fight cancer

Study Details

This research study is studying an immune-based cancer drug as a possible treatment for prostate cancer. The drug involved in this study is: -Nivolumab

Key Dates

Start date
Oct 18, 2018
Status verified
Apr 2026
Primary completion
Sep 30, 2023
Completion
Dec 31, 2026

Study Design

Enrollment
29 participants (actual)
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: PD-L1 Negative
    -Nivolumab will be given on day 1 of a 28-day cycle intravenously
  • Experimental: PD-L1 Positive
    -Nivolumab will be given on day 1 of a 28-day cycle intravenously

Primary Outcome Measure

Disease Control Rate at 12 Weeks [ Time Frame: 12 weeks ]

Locations (5)

FacilityCityStateZIPSite coordinators
Beth Israel Deaconess Medical CenterBostonMassachusetts02215-
Dana Farber Cancer InstituteBostonMassachusetts02215-
St. Elizabeth's Medical CenterBostonMassachusetts02135-
DFCI South ShoreSouth WeymouthMassachusetts02190-
DFCI LondonderryLondonderryNew Hampshire03053-

Related coverage on Hipa.ai

Find similar trials in Boston, MA

By condition
Prostate cancer
By specialty
OncologyProstate oncologyMen's healthUrology
By research site
Beth Israel Deaconess Medical Center· Boston, MADana Farber Cancer Institute· Boston, MASt. Elizabeth's Medical Center· Boston, MADFCI South Shore· South Weymouth, MADFCI Londonderry· Londonderry, NH

Related Studies